Search Results - xiaobo+mao

5 Results

Sort By:

The Efficacy of Nanozyme in Neurodegenerative Diseases

Unmet NeedOxidative stress and subsequent prion-like pathology is an essential driver n the pathogenesis of neurodegenerative diseases, including Parkinson’s Disease (PD and Alzheimer’s disease (AD). Currently, only symptomatic treatments are available, and there is a great unmet need to develop a cure. Technology OverviewDisclosed herein are novel...

Published: 3/14/2025 | Inventor(s): Xiaobo Mao, Shuya Li, Weiwei He

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Parkinson's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease, Technology Classifications > Therapeutic Modalities > Proteins

Disulfide Bond-free and Fibril-specific Nanobodies Prevent the Prion-like α-synuclein Spreading

Unmet NeedLewy bodies dementia (LBD) is one of the most common causes of dementia, including Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB). Both clinical and experimental observations support the hypothesis of prion-like α-syn driving α-synucleinopathy, hence targeting the prion-like α-syn may be a new approach to treat...

Published: 3/14/2025 | Inventor(s): Xiaobo Mao, Wenjing Wang, Yemima Raini, Yuqing Liu, Ramhari Kumbhar

Keywords(s):

Category(s):

PtCu Nanozyme Scavenging ROS for Prevention of Pathologic α-Synuclein Transmission

Description: Unmet Need Parkinson’s disease (PD) is the second most common neurodegenerative disorder characterized with misfolded α-synuclein (α-syn) accumulation in Lewy bodies (LB). Although some α-syn mutations have been associated with familial PD, the majority cases are sporadic with unknown etiology. Tremendous efforts have been made to develop...

Published: 3/14/2025 | Inventor(s): Xiaobo Mao, Weiwei He, Yuqing Liu

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Neurodegeneration, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers

Platform for drug screening in human neurons

Unmet NeedThe WHO has predicted that neurological disorders (NDs) will become the second leading cause of death in 20 years after cardiovascular diseases. Various proteins have been identified to aggregate and accumulate in the brain depending on the indication: amyloid-beta or tau in Alzheimer’s Disease, alpha-synuclein in Parkinson’s disease, and...

Published: 3/14/2025 | Inventor(s): Gabsang Lee, Minseong Kim, Eun Ra, Han Seok Ko, Xiaobo Mao

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology > Parkinson’s Disease, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Therapeutic Modalities

Identification of LAG3 as the α-synuclein Neuronal Transmission Receptor

Unmet Need: Parkinson’s disease (PD) is the second most common neurodegenerative disorder and leads to slowness of movement, tremor, rigidity, and, in the later stages of PD, cognitive impairment. Pathologically, PD is characterized by the accumulation of α-synuclein in Lewy bodies and neurites. Emerging evidence indicates that the pathogenesis of Parkinson's...

Published: 3/13/2025 | Inventor(s): Ted Dawson, Valina Dawson, Han Seok Ko, Xiaobo Mao, Dario Vignali, Creg Workman

Keywords(s): Biomarker, CNS and Neurological Disorders, Disease Indication, Mechanism-of-action Biomarker, Parkinson's Disease, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology > Parkinson's Disease, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities